Developer docs
API playgroundTry for free, no card

Search company profiles

NstarX

Full company profile

uuid0022g7e

Namestring
NstarX
Legal namestring
NASTRX, Inc.
Websiteurl
nastrx.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

NASTRX, Inc. is a privately held structural biology services company founded in 2004 and headquartered in Chicago, Illinois. The firm provides contract crystallography and structural proteomics services to pharmaceutical and biotechnology companies, centered on synchrotron X-ray diffraction data collection at the Advanced Photon Source (APS), 3-D structure determination of protein-ligand complexes, and de novo protein structure determination. Its service portfolio includes the branded RapidDetermination line (Type 1 for initial electron density identification and ligand placement, and Type 2 for de novo phasing from MAD/SAD or MIR/SIR data), StructureComplete for publication-quality refinement, Structural Analysis, and a Structural Proteomic Informatics solution intended for structure-based drug design programs.

The business operates as a B2B professional services firm on a contract basis. Clients ship frozen crystal samples to NASTRX, the firm collects and processes data at APS, posts results in real time to a secure server, and returns raw images, scaled data, summary reports, and frozen samples to the client. Pricing is not publicly disclosed and is negotiated per engagement. Customer targeting is vertical — pharmaceutical and biotechnology companies engaged in drug discovery — with no named logos or publicly disclosed customer base.

The company is led by a two-person executive team: David E. Do, J.D., M.B.A. (CEO and Chief Legal Counsel) and Joseph S. Brunzelle, Ph.D. (CSO and President). Headcount is reported at 1-10 employees, and there is no evidence of external venture or private equity funding, a parent organization, or material geographic expansion. The most recent peer-reviewed publications listed on the company website are dated 2008, and the public-facing site is minimalist, suggesting a static, boutique-style operating footprint with no visible recent investment in growth, technology refresh, or business development.

Short descriptiontext

NASTRX is a Chicago-based contract crystallography firm providing synchrotron X-ray structure determination, refinement, and structural proteomic informatics services to pharmaceutical and biotechnology clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
structural biology services, X-ray crystallography, protein structure determination, structural proteomics, drug discovery support
Industry1 code
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Testing Laboratories8734
Product category
Structural Biology Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Crystallography Services
TypeProfessional Services
Description

B2B contract services for pharmaceutical and biotechnology companies including X-ray diffraction data collection, structure determination, and structural analysis. Services are customized to client needs with real-time data posting and comprehensive reporting.

nastrx.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1RapidDetermination
Description

Structure determination service broken into two types: Type 1 is initial electron density identification and placement of ligand compounds with results posted in real time; Type 2 is initial de novo determination phases from MAD/SAD or MIR/SIR X-ray diffraction data.

nastrx.com
+2 more records
Core offering1 text field

NASTRX provides contract crystallography and structural proteomics services to pharmaceutical and biotechnology companies. The company performs synchrotron X-ray data collection at the Advanced Photon Source (APS), 3-D structure determination of protein-ligand complexes, de novo protein structure determination, and integrated structural proteomic informatics for structure-based drug design programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Real-time data posting enables faster decision-making in drug discovery timelines
+1 more record
Product overview1 text field

NASTRX provides integrated structural proteomics services for pharmaceutical and biotechnology companies. The core offering centers on Contract Crystallography services, encompassing synchrotron X-ray data collection at the Advanced Photon Source (APS), data analysis, and structure determination. The RapidDetermination service (Type 1 for ligand placement and Type 2 for de novo phase determination) enables rapid structural insights, while StructureComplete delivers publication-quality refined structures. These are complemented by Structural Analysis and Structural Proteomic Informatics solutions that support structure-based drug design programs. The company was founded in 2004 and specializes in customization for client-specific needs.

Product and service5 records
1Contract Crystallography
CategoryContract Research Services
Description

Core service providing synchrotron X-ray data collection at the Advance Photon Source (APS) and comprehensive data analysis. Frozen crystal samples are shipped to NASTRX, processed, integrated and scaled, with results posted in real time on a secure server and final deliverables shipped back to the client. Intended for pharmaceutical and biotechnology companies needing protein crystallography data.

2RapidDetermination
CategoryStructure Determination Services
Description

Structure determination service offered in two types: Type 1 performs initial electron density identification and placement of ligand compounds with results posted in real time on a secure server; Type 2 performs initial de novo determination phases from MAD/SAD or MIR/SIR X-ray diffraction data. Targeted at pharma and biotech clients needing rapid crystallographic insights.

3StructureComplete
CategoryStructure Refinement Services
Description

Full and final refinement of a macromolecular molecule to publication-quality standards. Serves pharma and biotech researchers who require publishable crystal structures.

4Structural Proteomic Informatics
CategoryStructural Informatics Solutions
Description

Fully integrated structural proteomic informatics solution for structure-based drug design programs. Supports pharma and biotech clients in translating crystal structures into actionable drug design insights.

5De Novo Protein Structure Services
CategoryStructure Determination Services
Description

De novo determination services for new target projects, covering protein structure elucidation from first principles for clients pursuing novel targets.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Advance Photon Source (APS)
Strategic tierCoreTypeTechnology or Integration
Description

NASTRX conducts synchrotron X-ray data collection at the Advanced Photon Source (APS), a national user facility. This partnership provides access to high-intensity X-ray sources essential for protein crystallography data collection, which is central to NASTRX's service offerings for structural biology research.

nastrx.com
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Xtal BioStructures is a U.S.-based contract crystallography provider offering protein crystallization, X-ray data collection, and structure determination services to pharma and biotech — a closely comparable specialist peer to NASTRX.

TypeBroad incumbent
Description

Bruker is a major scientific instrument vendor with a structural biology portfolio (X-ray crystallography and cryo-EM systems) and adjacent service offerings, positioning it as a broad incumbent in the same end markets as NASTRX.

TypeEmerging player
Description

Schrödinger is a computational SBDD platform company whose physics-based structure prediction and informatics overlap with NASTRX's Structural Proteomic Informatics offering — an emerging, partially overlapping peer in the SBDD value chain.

TypeBroad incumbent
Description

Rigaku is a global manufacturer of X-ray crystallography instruments and also provides protein crystallography services and beamline support, making it a broad incumbent that competes with NASTRX in both equipment and structural biology services.

TypeDirect peer
Description

SARomics is a Sweden-based structural biology services provider focused on X-ray crystallography, SBDD, and protein–ligand complex determination, closely mirroring NASTRX's core offering for pharma/biotech drug discovery.

TypeEmerging player
Description

Domainex is an integrated UK CRO with structural biology (including X-ray crystallography and cryo-EM) embedded in a broader drug discovery offering — comparable as an emerging player that bundles crystallography with adjacent services NASTRX provides.

TypeDirect peer
Description

Crelux is a structural biology CRO specializing in X-ray crystallography and protein production for structure-based drug design, now part of Proteros — a direct head-to-head competitor to NASTRX in contract SBDD services.

TypeBroad incumbent
Description

Charles River is a large, diversified CRO with structural biology capabilities among many other discovery services — a broad incumbent comparable in customer base (pharma/biotech) though structurally different in scale and scope.

TypeDirect peer
Description

Proteros is a Germany-based structural biology CRO offering X-ray crystallography, cryo-EM, and biophysics services to pharma and biotech — the most direct functional comparable to NASTRX's contract crystallography and structure determination business.

TypeDirect peer
Description

ZoBio is a Netherlands-based structural biology CRO providing protein crystallography, fragment-based lead discovery, and biophysics for pharma — directly comparable in service mix and customer base to NASTRX.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NstarX

Structural Biology Servicesnastrx.com

NASTRX is a Chicago-based contract crystallography firm providing synchrotron X-ray structure determination, refinement, and structural proteomic informatics services to pharmaceutical and biotechnology clients.

What NstarX does

NASTRX, Inc. is a privately held structural biology services company founded in 2004 and headquartered in Chicago, Illinois. The firm provides contract crystallography and structural proteomics services to pharmaceutical and biotechnology companies, centered on synchrotron X-ray diffraction data collection at the Advanced Photon Source (APS), 3-D structure determination of protein-ligand complexes, and de novo protein structure determination. Its service portfolio includes the branded RapidDetermination line (Type 1 for initial electron density identification and ligand placement, and Type 2 for de novo phasing from MAD/SAD or MIR/SIR data), StructureComplete for publication-quality refinement, Structural Analysis, and a Structural Proteomic Informatics solution intended for structure-based drug design programs.

The business operates as a B2B professional services firm on a contract basis. Clients ship frozen crystal samples to NASTRX, the firm collects and processes data at APS, posts results in real time to a secure server, and returns raw images, scaled data, summary reports, and frozen samples to the client. Pricing is not publicly disclosed and is negotiated per engagement. Customer targeting is vertical — pharmaceutical and biotechnology companies engaged in drug discovery — with no named logos or publicly disclosed customer base.

The company is led by a two-person executive team: David E. Do, J.D., M.B.A. (CEO and Chief Legal Counsel) and Joseph S. Brunzelle, Ph.D. (CSO and President). Headcount is reported at 1-10 employees, and there is no evidence of external venture or private equity funding, a parent organization, or material geographic expansion. The most recent peer-reviewed publications listed on the company website are dated 2008, and the public-facing site is minimalist, suggesting a static, boutique-style operating footprint with no visible recent investment in growth, technology refresh, or business development.

NstarX firmographics

Firmographics
Name
NstarX
Legal name
NASTRX, Inc.
Website
https://nastrx.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
NASTRX is a Chicago-based contract crystallography firm providing synchrotron X-ray structure determination, refinement, and structural proteomic informatics services to pharmaceutical and biotechnology clients.
Ownership category
akta.pro rank

NstarX industry classification

Industry
Product category
Structural Biology Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Structural biology services
  • X-ray crystallography
  • Protein structure determination
  • Structural proteomics
  • Drug discovery support

Where NstarX is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Markets served

NstarX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

  1. Contract Crystallography Services: B2B contract services for pharmaceutical and biotechnology companies including X-ray diffraction data collection, structure determination, and structural analysis. Services are customized to client needs with real-time data posting and comprehensive reporting.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

NstarX product offering

Product offering

Core offering

NASTRX provides contract crystallography and structural proteomics services to pharmaceutical and biotechnology companies. The company performs synchrotron X-ray data collection at the Advanced Photon Source (APS), 3-D structure determination of protein-ligand complexes, de novo protein structure determination, and integrated structural proteomic informatics for structure-based drug design programs.

Product overview

NASTRX provides integrated structural proteomics services for pharmaceutical and biotechnology companies. The core offering centers on Contract Crystallography services, encompassing synchrotron X-ray data collection at the Advanced Photon Source (APS), data analysis, and structure determination. The RapidDetermination service (Type 1 for ligand placement and Type 2 for de novo phase determination) enables rapid structural insights, while StructureComplete delivers publication-quality refined structures. These are complemented by Structural Analysis and Structural Proteomic Informatics solutions that support structure-based drug design programs. The company was founded in 2004 and specializes in customization for client-specific needs.

Differentiator

Problem solved

Functional benefit

Brands

  • RapidDetermination: Structure determination service broken into two types: Type 1 is initial electron density identification and placement of ligand compounds with results posted in real time; Type 2 is initial de novo determination phases from MAD/SAD or MIR/SIR X-ray diffraction data.
  • StructureComplete
  • Structural Proteomic Informatics

Products and services

  • Contract Crystallography Core service providing synchrotron X-ray data collection at the Advance Photon Source (APS) and comprehensive data analysis. Frozen crystal samples are shipped to NASTRX, processed, integrated and scaled, with results posted in real time on a secure server and final deliverables shipped back to the client. Intended for pharmaceutical and biotechnology companies needing protein crystallography data.
  • RapidDetermination Structure determination service offered in two types: Type 1 performs initial electron density identification and placement of ligand compounds with results posted in real time on a secure server; Type 2 performs initial de novo determination phases from MAD/SAD or MIR/SIR X-ray diffraction data. Targeted at pharma and biotech clients needing rapid crystallographic insights.
  • StructureComplete Full and final refinement of a macromolecular molecule to publication-quality standards. Serves pharma and biotech researchers who require publishable crystal structures.
  • Structural Proteomic Informatics Fully integrated structural proteomic informatics solution for structure-based drug design programs. Supports pharma and biotech clients in translating crystal structures into actionable drug design insights.
  • De Novo Protein Structure Services De novo determination services for new target projects, covering protein structure elucidation from first principles for clients pursuing novel targets.

Quantifiable outcome

  • Real-time data posting enables faster decision-making in drug discovery timelines
  • +1 more outcomes

Companies that use NstarX

Customer profile

Segments2 records

Ideal customer profiles2 records

NstarX technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NstarX partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Advance Photon Source (APS)coreTechnology or IntegrationNASTRX conducts synchrotron X-ray data collection at the Advanced Photon Source (APS), a national user facility. This partnership provides access to high-intensity X-ray sources essential for protein crystallography data collection, which is central to NASTRX's service offerings for structural biology research.

Scale indicators2 records

Recent moves4 records

Expansion highlights1 record

NstarX competitors and assessment

Company assessment

Direct peers

  • Xtal BioStructures: Xtal BioStructures is a U.S.-based contract crystallography provider offering protein crystallization, X-ray data collection, and structure determination services to pharma and biotech — a closely comparable specialist peer to NASTRX.
  • SARomics Biostructures: SARomics is a Sweden-based structural biology services provider focused on X-ray crystallography, SBDD, and protein–ligand complex determination, closely mirroring NASTRX's core offering for pharma/biotech drug discovery.
  • Crelux (a Proteros company): Crelux is a structural biology CRO specializing in X-ray crystallography and protein production for structure-based drug design, now part of Proteros — a direct head-to-head competitor to NASTRX in contract SBDD services.
  • Proteros: Proteros is a Germany-based structural biology CRO offering X-ray crystallography, cryo-EM, and biophysics services to pharma and biotech — the most direct functional comparable to NASTRX's contract crystallography and structure determination business.
  • ZoBio: ZoBio is a Netherlands-based structural biology CRO providing protein crystallography, fragment-based lead discovery, and biophysics for pharma — directly comparable in service mix and customer base to NASTRX.

Broad incumbents

  • Bruker: Bruker is a major scientific instrument vendor with a structural biology portfolio (X-ray crystallography and cryo-EM systems) and adjacent service offerings, positioning it as a broad incumbent in the same end markets as NASTRX.
  • Rigaku: Rigaku is a global manufacturer of X-ray crystallography instruments and also provides protein crystallography services and beamline support, making it a broad incumbent that competes with NASTRX in both equipment and structural biology services.
  • Charles River Laboratories: Charles River is a large, diversified CRO with structural biology capabilities among many other discovery services — a broad incumbent comparable in customer base (pharma/biotech) though structurally different in scale and scope.

Emerging players

  • Schrödinger: Schrödinger is a computational SBDD platform company whose physics-based structure prediction and informatics overlap with NASTRX's Structural Proteomic Informatics offering — an emerging, partially overlapping peer in the SBDD value chain.
  • Domainex: Domainex is an integrated UK CRO with structural biology (including X-ray crystallography and cryo-EM) embedded in a broader drug discovery offering — comparable as an emerging player that bundles crystallography with adjacent services NASTRX provides.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

NstarX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NstarX leadership team

Management profile

Number of profiles

Profiles2 records

NstarX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NstarX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NstarX

What does NstarX do?

NASTRX provides contract crystallography and structural proteomics services to pharmaceutical and biotechnology companies. The company performs synchrotron X-ray data collection at the Advanced Photon Source (APS), 3-D structure determination of protein-ligand complexes, de novo protein structure determination, and integrated structural proteomic informatics for structure-based drug design programs.

Is NstarX a public or private company?

NstarX is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was NstarX founded?

NstarX was founded in 2004. It employs 1 to 10 people.

Where is NstarX based?

NstarX is headquartered in Chicago, United States, in the North America region.

How does NstarX make money?

One revenue line is on record: contract Crystallography Services.

Who are NstarX's main competitors?

Direct peers on record are Xtal BioStructures, SARomics Biostructures, Crelux (a Proteros company), Proteros and ZoBio. Broad incumbents are Bruker, Rigaku and Charles River Laboratories. Emerging players are Schrödinger and Domainex.

Does NstarX have an API?

No public API is recorded for NstarX.

What industry is NstarX in?

NstarX's product category is Structural Biology Services. Its primary akta.pro industry code is HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 541714 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales